Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
about
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelThe NF-κB Pathway and Cancer Stem CellsImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersPI3K and AKT: Unfaithful Partners in CancerLigand-Independent EGFR SignalingMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateThe role of NF-κB in the pathogenesis of gliomaNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredA kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastomaCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaSerine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.Akt1 enhances CA916798 expression through mTOR pathwayA high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signalingmTORC2 in the center of cancer metabolic reprogrammingmTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesEGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cellsTORC2-a new player in genome stabilityQuinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerMicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic targetmTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.Conditional astroglial Rictor overexpression induces malignant glioma in miceThe mTOR signaling pathway as a treatment target for intracranial neoplasmsEmerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.Significance of filamin A in mTORC2 function in glioblastomaOrthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
P2860
Q21133610-752331F7-26E9-4C9D-9CD0-F7131799F181Q26750605-FCC7F8D5-9484-4624-98B0-F596E62BA7FCQ26751473-5B5927A9-2A24-44F5-A832-1F0EAFE17B89Q26781367-618865C9-29E6-436D-A6A0-F3EEF975545DQ26797495-5BD4ECFB-0FBC-49F2-B9D2-244179CB96ADQ26822717-C56A4D23-6AB7-40BB-B036-9F5AE61837FCQ26825502-75F4B5C0-454F-4DAD-9826-36D160329D02Q26830388-5DC1F0F9-43E7-462C-AA50-ABAF3CBB27CCQ27013006-E9456CA9-9ED6-4BF3-A778-728CC1A8B433Q27015045-4825A008-A957-4910-9FA8-3EBDEB37C8A4Q27324733-409653C9-249E-4241-8D40-45FA59CD31D6Q28087306-ECC086C7-2275-4BC3-B2A6-F4E3BBCFF65CQ28115436-0D6530B3-97E1-47AD-BF1E-CF4B393D82CEQ28487802-F8A46A32-6CD7-4F14-B1DC-6FB077B2A092Q30396975-23851984-0630-4173-BCBC-EC6068D9B52DQ33276239-9F630725-9918-4067-BABD-25A3D7677D4BQ33435610-39492EFC-D853-4EBD-BD59-D854EDE14CBCQ33466722-0CB5E248-B660-4B51-A2E3-4C33E74F0AB3Q33615797-836E6196-DCF4-41FD-969A-30301711D40EQ33643498-F9B9D2F1-DC2A-47AC-B2F7-EE3D1D68B05FQ33798469-8633C53C-4191-45FC-A300-C186423D3E78Q33831466-EF253059-3B05-4077-88B0-2A56B670ECA7Q33884658-62BD44A3-C45D-4DEB-9A7B-24FB5BD66D22Q33925544-69F26FF5-DE6B-4C52-BB04-8618A8B530AEQ34060669-3DB952C8-CE02-4C9E-864D-D719663E9187Q34131149-8F9A4447-81CE-4F6D-AC92-BDED0EBC6B23Q34143354-62087C62-17C1-4F21-AED0-5E7ACBFE3548Q34293127-6D020A5E-47D7-410C-ABDB-74E61C28BA14Q34365897-4BABE180-DAFC-413F-90E2-137FC52F491BQ34394233-224FD87C-8FAB-4DD7-9FED-F74471E6BA20Q34451068-083F00D8-B9EF-4002-9176-8D4B915593FAQ34886859-AD5DA205-8CAC-4A30-AC62-214D4822B7FBQ34974398-CC0FFBDC-22C8-4CBC-969F-EE06FD1854F0Q34986247-964C4B49-5E84-44FD-AB9E-270D49BDA76CQ35287890-0B7E77D2-7627-4BBD-A1F5-DB8920FFE70CQ35408838-52964784-49D8-40A4-99E3-19781DB9602EQ35809950-5BF52EB8-F5DB-4561-A096-5F88E9AA43E6Q35828426-33FA7BA3-38A5-4542-BCE7-77593F78FEE5Q35843230-B130947D-EDC6-40F5-A02C-4D285A8238C0Q35910243-53AE21F8-1605-4C5A-A139-AB55097937F8
P2860
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@en
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@nl
type
label
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@en
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@nl
prefLabel
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@en
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@nl
P2093
P2860
P1433
P1476
Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.
@en
P2093
Albert S Baldwin
Ali Nael Amzajerdi
Amanda Rinkenbaugh
Beatrice Gini
Brendan D Manning
Christian C Dibble
David Akhavan
David Nathanson
Deliang Guo
Hancai Dan
P2860
P304
P356
10.1158/2159-8290.CD-11-0124
P577
2011-09-13T00:00:00Z